vs
Side-by-side financial comparison of Bio-Techne (TECH) and TIC Solutions, Inc. (TIC). Click either name above to swap in a different company.
TIC Solutions, Inc. is the larger business by last-quarter revenue ($508.3M vs $295.9M, roughly 1.7× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -9.3%, a 22.1% gap on every dollar of revenue.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
TECH vs TIC — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $508.3M |
| Net Profit | $38.0M | $-47.2M |
| Gross Margin | 64.6% | 35.2% |
| Operating Margin | 18.4% | -3.8% |
| Net Margin | 12.8% | -9.3% |
| Revenue YoY | -6.4% | — |
| Net Profit YoY | 68.3% | — |
| EPS (diluted) | $0.24 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $295.9M | $508.3M | ||
| Q3 25 | — | $473.9M | ||
| Q2 25 | $317.0M | $313.9M | ||
| Q1 25 | $316.2M | $234.2M | ||
| Q4 24 | $297.0M | — | ||
| Q3 24 | $289.5M | — | ||
| Q2 24 | $306.1M | — | ||
| Q1 24 | $303.4M | — |
| Q4 25 | $38.0M | $-47.2M | ||
| Q3 25 | — | $-13.9M | ||
| Q2 25 | $-17.7M | $-233.0K | ||
| Q1 25 | $22.6M | $-25.8M | ||
| Q4 24 | $34.9M | — | ||
| Q3 24 | $33.6M | — | ||
| Q2 24 | $40.6M | — | ||
| Q1 24 | $49.1M | — |
| Q4 25 | 64.6% | 35.2% | ||
| Q3 25 | — | 32.2% | ||
| Q2 25 | 62.7% | 23.6% | ||
| Q1 25 | 67.9% | 18.6% | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | — | ||
| Q2 24 | 66.4% | — | ||
| Q1 24 | 67.4% | — |
| Q4 25 | 18.4% | -3.8% | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | -7.5% | 5.8% | ||
| Q1 25 | 12.2% | -4.0% | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 13.8% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 22.1% | — |
| Q4 25 | 12.8% | -9.3% | ||
| Q3 25 | — | -2.9% | ||
| Q2 25 | -5.6% | -0.1% | ||
| Q1 25 | 7.1% | -11.0% | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 11.6% | — | ||
| Q2 24 | 13.3% | — | ||
| Q1 24 | 16.2% | — |
| Q4 25 | $0.24 | — | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.26 | — | ||
| Q1 24 | $0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $439.5M |
| Total DebtLower is stronger | $260.0M | $1.6B |
| Stockholders' EquityBook value | $2.0B | $2.2B |
| Total Assets | $2.5B | $4.4B |
| Debt / EquityLower = less leverage | 0.13× | 0.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.9M | $439.5M | ||
| Q3 25 | — | $164.4M | ||
| Q2 25 | $162.2M | $130.1M | ||
| Q1 25 | $140.7M | $155.7M | ||
| Q4 24 | $177.5M | — | ||
| Q3 24 | $187.5M | — | ||
| Q2 24 | $152.9M | — | ||
| Q1 24 | $145.3M | — |
| Q4 25 | $260.0M | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $346.0M | $751.3M | ||
| Q1 25 | $330.0M | $752.4M | ||
| Q4 24 | $300.0M | — | ||
| Q3 24 | $300.0M | — | ||
| Q2 24 | $319.0M | — | ||
| Q1 24 | $389.0M | — |
| Q4 25 | $2.0B | $2.2B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | $1.9B | $1.2B | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $2.5B | $4.4B | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | $2.6B | $2.2B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | 0.13× | 0.74× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | 0.18× | 0.64× | ||
| Q1 25 | 0.16× | 0.67× | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 0.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $49.7M |
| Free Cash FlowOCF − Capex | — | $37.1M |
| FCF MarginFCF / Revenue | — | 7.3% |
| Capex IntensityCapex / Revenue | — | 2.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $61.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $49.7M | ||
| Q3 25 | — | $19.0M | ||
| Q2 25 | $98.2M | $-6.5M | ||
| Q1 25 | $41.1M | $32.8M | ||
| Q4 24 | $84.3M | — | ||
| Q3 24 | $63.9M | — | ||
| Q2 24 | $75.5M | — | ||
| Q1 24 | $81.0M | — |
| Q4 25 | — | $37.1M | ||
| Q3 25 | — | $10.3M | ||
| Q2 25 | $93.3M | $-14.5M | ||
| Q1 25 | $31.0M | $28.3M | ||
| Q4 24 | $77.5M | — | ||
| Q3 24 | $54.7M | — | ||
| Q2 24 | $57.5M | — | ||
| Q1 24 | $64.5M | — |
| Q4 25 | — | 7.3% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | 29.4% | -4.6% | ||
| Q1 25 | 9.8% | 12.1% | ||
| Q4 24 | 26.1% | — | ||
| Q3 24 | 18.9% | — | ||
| Q2 24 | 18.8% | — | ||
| Q1 24 | 21.3% | — |
| Q4 25 | — | 2.5% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 3.2% | 1.9% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 5.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 2.42× | — | ||
| Q3 24 | 1.90× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
TIC
| Consulting Engineering Segment | $300.1M | 59% |
| Geospatial Segment | $131.3M | 26% |
| Fixed Unit Price Contracts | $54.3M | 11% |
| Other | $22.6M | 4% |
